Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Addressing health disparities in type 1 diabetes through peer mentorship.

Walker AF, Haller MJ, Gurka MJ, Morris HL, Bruggeman B, Miller K, Foster N, Anez Zabala C, Schatz DA.

Pediatr Diabetes. 2019 Oct 16. doi: 10.1111/pedi.12935. [Epub ahead of print]

PMID:
31617648
2.

Advances in Type 1 Diabetes Technology Over the Last Decade.

Zimmerman C, Albanese-O'Neill A, Haller MJ.

Eur Endocrinol. 2019 Aug;15(2):70-76. doi: 10.17925/EE.2019.15.2.70. Epub 2019 Aug 16. Review.

3.

Temporal Analysis of Amylase Expression in Control, Autoantibody Positive, and Type 1 Diabetes Pancreatic Tissues.

Kusmartseva I, Beery M, Hiller H, Padilla M, Selman S, Posgai A, Nick HS, Campbell-Thompson M, Schatz DA, Haller MJ, Wasserfall CH, Atkinson MA.

Diabetes. 2019 Oct 9. pii: db190554. doi: 10.2337/db19-0554. [Epub ahead of print]

PMID:
31597639
4.

Designing Online and Mobile Diabetes Education for Fathers of Children With Type 1 Diabetes: Mixed Methods Study.

Albanese-O'Neill A, Schatz DA, Thomas N, Bernhardt JM, Cook CL, Haller MJ, Bernier AV, Silverstein JH, Westen SC, Elder JH.

JMIR Diabetes. 2019 Aug 6;4(3):e13724. doi: 10.2196/13724.

5.

Human Factors Associated with Continuous Glucose Monitor Use in Patients with Diabetes: A Systematic Review.

Smith MB, Albanese-O'Neill A, Macieira TGR, Yao Y, Abbatematteo JM, Lyon D, Wilkie DJ, Haller MJ, Keenan GM.

Diabetes Technol Ther. 2019 Oct;21(10):589-601. doi: 10.1089/dia.2019.0136. Epub 2019 Aug 20.

PMID:
31335196
6.

Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network.

McGill JB, Wu M, Pop-Busui R, Mizokami-Stout K, Tamborlane WV, Aleppo G, Gubitosi-Klug RA, Haller MJ, Willi SM, Foster NC, Zimmerman C, Libman I, Polsky S, Rickels MR.

J Diabetes Complications. 2019 Oct;33(10):107400. doi: 10.1016/j.jdiacomp.2019.06.005. Epub 2019 Jun 26.

PMID:
31279735
7.

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9.

PMID:
30967424
8.

Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children.

Jacobsen LM, Larsson HE, Tamura RN, Vehik K, Clasen J, Sosenko J, Hagopian WA, She JX, Steck AK, Rewers M, Simell O, Toppari J, Veijola R, Ziegler AG, Krischer JP, Akolkar B, Haller MJ; TEDDY Study Group.

Pediatr Diabetes. 2019 May;20(3):263-270. doi: 10.1111/pedi.12812. Epub 2019 Jan 29.

PMID:
30628751
9.

Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes.

Campbell-Thompson ML, Filipp SL, Grajo JR, Nambam B, Beegle R, Middlebrooks EH, Gurka MJ, Atkinson MA, Schatz DA, Haller MJ.

Diabetes Care. 2019 Feb;42(2):281-287. doi: 10.2337/dc18-1512. Epub 2018 Dec 14.

PMID:
30552130
10.

Transition Education for Young Adults With Type 1 Diabetes: Pilot Feasibility Study for a Group Telehealth Intervention.

Albanese-O'Neill A, Beauchamp G, Thomas N, Westen SC, Johnson N, Schatz D, Haller MJ.

JMIR Diabetes. 2018 Nov 5;3(4):e10909. doi: 10.2196/10909.

11.

Objectively Measured Adherence in Adolescents With Type 1 Diabetes on Multiple Daily Injections and Insulin Pump Therapy.

Westen SC, Warnick JL, Albanese-O'Neill A, Schatz DA, Haller MJ, Entessari M, Janicke DM.

J Pediatr Psychol. 2019 Jan 1;44(1):21-31. doi: 10.1093/jpepsy/jsy064.

PMID:
30184209
12.

Immune Mechanisms and Pathways Targeted in Type 1 Diabetes.

Jacobsen LM, Newby BN, Perry DJ, Posgai AL, Haller MJ, Brusko TM.

Curr Diab Rep. 2018 Aug 30;18(10):90. doi: 10.1007/s11892-018-1066-5. Review.

PMID:
30168021
13.

ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents.

Couper JJ, Haller MJ, Greenbaum CJ, Ziegler AG, Wherrett DK, Knip M, Craig ME.

Pediatr Diabetes. 2018 Oct;19 Suppl 27:20-27. doi: 10.1111/pedi.12734. No abstract available.

PMID:
30051639
14.

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes Care. 2018 Sep;41(9):1917-1925. doi: 10.2337/dc18-0494. Epub 2018 Jul 16.

15.

Geographic access to endocrinologists for Florida's publicly insured children with diabetes.

Walker AF, Hall JM, Shenkman EA, Gurka MJ, Morris HL, Haller MJ, Rohrs HJ, Salazar KR, Shatz DA.

Am J Manag Care. 2018 Mar;24(4 Spec No.):SP106-SP109. No abstract available.

16.

Family adjustment to diabetes diagnosis in children: Can participation in a study on type 1 diabetes genetic risk be helpful?

Smith LB, Liu X, Johnson SB, Tamura R, Elding Larsson H, Ahmed S, Veijola R, Haller MJ, Akolkar B, Hagopian WA, Rewers MJ, Krischer J, Steck AK; TEDDY study group.

Pediatr Diabetes. 2018 Aug;19(5):1025-1033. doi: 10.1111/pedi.12674. Epub 2018 May 2.

17.

Understanding Pre-Type 1 Diabetes: The Key to Prevention.

Jacobsen LM, Haller MJ, Schatz DA.

Front Endocrinol (Lausanne). 2018 Mar 6;9:70. doi: 10.3389/fendo.2018.00070. eCollection 2018. Review.

18.

Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling.

Perry DJ, Wasserfall CH, Oram RA, Williams MD, Posgai A, Muir AB, Haller MJ, Schatz DA, Wallet MA, Mathews CE, Atkinson MA, Brusko TM.

Sci Rep. 2018 Mar 14;8(1):4529. doi: 10.1038/s41598-018-22574-5.

19.

Presymptomatic screening for autoimmune β-cell disorder: Baby steps toward prevention?

Jacobsen LM, Anhalt H, Haller MJ.

Pediatr Diabetes. 2018 Feb;19(1):11-13. doi: 10.1111/pedi.12620. No abstract available.

PMID:
29368416
20.

T Cell Receptor Profiling in Type 1 Diabetes.

Jacobsen LM, Posgai A, Seay HR, Haller MJ, Brusko TM.

Curr Diab Rep. 2017 Oct 11;17(11):118. doi: 10.1007/s11892-017-0946-4. Review.

21.

Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children.

Elding Larsson H, Lynch KF, Lönnrot M, Haller MJ, Lernmark Å, Hagopian WA, She JX, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Rewers MJ, Hyöty H; TEDDY Study Group.

Diabetologia. 2018 Jan;61(1):193-202. doi: 10.1007/s00125-017-4448-3. Epub 2017 Oct 9.

22.

Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident β-cell autoantibodies.

Lynch KF, Lee HS, Törn C, Vehik K, Krischer JP, Larsson HE, Haller MJ, Hagopian WA, Rewers MJ, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Hyöty H, Bonifacio E, Lernmark Å; TEDDY Study Group.

J Autoimmun. 2018 Jan;86:93-103. doi: 10.1016/j.jaut.2017.09.005. Epub 2017 Sep 21.

23.

High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes.

Jacobsen LM, Haller MJ, Parish A, Gurka MJ, Levine SR, Wasserfall C, Campbell-Thompson M, Kaddis J, Pugliese A, Atkinson MA, Schatz DA.

Diabetes Care. 2017 Sep;40(9):e122-e123. doi: 10.2337/dc17-0996. Epub 2017 Jul 5. No abstract available.

PMID:
28679687
24.

Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults.

Marcial GE, Ford AL, Haller MJ, Gezan SA, Harrison NA, Cai D, Meyer JL, Perry DJ, Atkinson MA, Wasserfall CH, Garrett T, Gonzalez CF, Brusko TM, Dahl WJ, Lorca GL.

Front Immunol. 2017 Jun 12;8:655. doi: 10.3389/fimmu.2017.00655. eCollection 2017.

25.

Analgesic antipyretic use among young children in the TEDDY study: no association with islet autoimmunity.

Lundgren M, Steed LJ, Tamura R, Jonsdottir B, Gesualdo P, Crouch C, Sjöberg M, Hansson G, Hagopian WA, Ziegler AG, Rewers MJ, Lernmark Å, Toppari J, She JX, Akolkar B, Krischer JP, Haller MJ, Elding Larsson H; TEDDY Study Group.

BMC Pediatr. 2017 May 16;17(1):127. doi: 10.1186/s12887-017-0884-y.

26.

Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.

Seay HR, Putnam AL, Cserny J, Posgai AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, Brown KS, Balavage KT, Peters LD, Bushdorf AN, Atkinson MA, Bluestone JA, Haller MJ, Brusko TM.

Mol Ther Methods Clin Dev. 2016 Dec 24;4:178-191. doi: 10.1016/j.omtm.2016.12.003. eCollection 2017 Mar 17.

27.

Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls.

Steck AK, Larsson HE, Liu X, Veijola R, Toppari J, Hagopian WA, Haller MJ, Ahmed S, Akolkar B, Lernmark Å, Rewers MJ, Krischer JP; and the TEDDY Study Group.

Pediatr Diabetes. 2017 Dec;18(8):794-802. doi: 10.1111/pedi.12485. Epub 2017 Jan 27.

28.

Serum Trypsinogen Levels in Type 1 Diabetes.

Li X, Campbell-Thompson M, Wasserfall CH, McGrail K, Posgai A, Schultz AR, Brusko TM, Shuster J, Liang F, Muir A, Schatz D, Haller MJ, Atkinson MA.

Diabetes Care. 2017 Apr;40(4):577-582. doi: 10.2337/dc16-1774. Epub 2017 Jan 23.

29.

Poor Adherence to Ketone Testing in Patients With Type 1 Diabetes.

Albanese-O'Neill A, Wu M, Miller KM, Jacobsen L, Haller MJ, Schatz D; T1D Exchange Clinic Network.

Diabetes Care. 2017 Apr;40(4):e38-e39. doi: 10.2337/dc16-2620. Epub 2017 Jan 18. No abstract available.

PMID:
28100607
30.

Treatable Diabetic Retinopathy Is Extremely Rare Among Pediatric T1D Exchange Clinic Registry Participants.

Beauchamp G, Boyle CT, Tamborlane WV, Miller KM, Libman IM, Haller MJ, Beck RW; T1D Exchange Clinic Network.

Diabetes Care. 2016 Dec;39(12):e218-e219. Epub 2016 Oct 7. No abstract available.

31.

Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity.

Bonifacio E, Mathieu C, Nepom GT, Ziegler AG, Anhalt H, Haller MJ, Harrison LC, Hebrok M, Kushner JA, Norris JM, Peakman M, Powers AC, Todd JA, Atkinson MA.

Diabetologia. 2017 Jan;60(1):35-38. Epub 2016 Oct 26.

32.

Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.

Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA, Schatz DA.

Diabetes. 2016 Dec;65(12):3765-3775. Epub 2016 Sep 26.

33.

Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264-270.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Oct;39(10):e193-4. doi: 10.2337/dci16-0025. No abstract available.

34.

Updates on Immune Therapies in Type 1 Diabetes.

Nambam B, Haller MJ.

Eur Endocrinol. 2016 Aug;12(2):89-95. doi: 10.17925/EE.2016.12.02.89. Epub 2016 Aug 28. Review.

35.

The DIPP project: 20 years of discovery in type 1 diabetes.

Haller MJ, Schatz DA.

Pediatr Diabetes. 2016 Jul;17 Suppl 22:5-7. doi: 10.1111/pedi.12398. No abstract available.

PMID:
27411430
36.

Premeal insulin decreases arterial stiffness in children with type 1 diabetes.

Meehan CS, Kethireddy PL, Ashcraft JK, Shuster JJ, Haller MJ.

Pediatr Diabetes. 2017 Jun;18(4):311-314. doi: 10.1111/pedi.12389. Epub 2016 May 13.

PMID:
27174580
37.

Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.

Cani AK, Soliman M, Hovelson DH, Liu CJ, McDaniel AS, Haller MJ, Bratley JV, Rahrig SE, Li Q, Briceño CA, Tomlins SA, Rao RC.

Mod Pathol. 2016 Jul;29(7):685-97. doi: 10.1038/modpathol.2016.79. Epub 2016 Apr 22.

38.

Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.

Harms PW, Hovelson DH, Cani AK, Omata K, Haller MJ, Wang ML, Arps D, Patel RM, Fullen DR, Wang M, Siddiqui J, Andea A, Tomlins SA.

Hum Pathol. 2016 May;51:25-31. doi: 10.1016/j.humpath.2015.12.015. Epub 2016 Jan 7.

PMID:
27067779
39.

Growth and Risk for Islet Autoimmunity and Progression to Type 1 Diabetes in Early Childhood: The Environmental Determinants of Diabetes in the Young Study.

Elding Larsson H, Vehik K, Haller MJ, Liu X, Akolkar B, Hagopian W, Krischer J, Lernmark Å, She JX, Simell O, Toppari J, Ziegler AG, Rewers M; TEDDY Study Group.

Diabetes. 2016 Jul;65(7):1988-95. doi: 10.2337/db15-1180. Epub 2016 Mar 18.

40.

Identification of tissue-specific cell death using methylation patterns of circulating DNA.

Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgård B, Blennow K, Zetterberg H, Spalding K, Haller MJ, Wasserfall CH, Schatz DA, Greenbaum CJ, Dorrell C, Grompe M, Zick A, Hubert A, Maoz M, Fendrich V, Bartsch DK, Golan T, Ben Sasson SA, Zamir G, Razin A, Cedar H, Shapiro AM, Glaser B, Shemer R, Dor Y.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1826-34. doi: 10.1073/pnas.1519286113. Epub 2016 Mar 14.

41.

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Feb;39(2):264-70. doi: 10.2337/dc15-1498. Epub 2015 Dec 17.

42.

Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.

Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, Simmons JH, Haller MJ, Raman S, Tamborlane WV, Coffey JK, Saenz AM, Beck RW, Nadeau KJ; T1D Exchange Clinic Network Metformin RCT Study Group.

JAMA. 2015 Dec 1;314(21):2241-50. doi: 10.1001/jama.2015.16174.

43.

Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes.

Haller MJ, Atkinson MA, Wasserfall CH, Brusko TM, Mathews CE, Hulme M, Cintron M, Shuster J, McGrail K, Posgai A, Schatz D.

Clin Exp Immunol. 2016 Mar;183(3):350-7. doi: 10.1111/cei.12731. Epub 2015 Dec 7.

44.

Screening for T1D risk to reduce DKA is not economically viable.

Meehan C, Fout B, Ashcraft J, Schatz DA, Haller MJ.

Pediatr Diabetes. 2015 Dec;16(8):565-72. doi: 10.1111/pedi.12313. Epub 2015 Sep 22.

PMID:
26392298
45.

Can we prevent type 1 diabetes?

Beauchamp G, Haller MJ.

Curr Diab Rep. 2015 Nov;15(11):86. doi: 10.1007/s11892-015-0658-6. Review.

PMID:
26370697
46.

The influence of type 1 diabetes on pancreatic weight.

Campbell-Thompson ML, Kaddis JS, Wasserfall C, Haller MJ, Pugliese A, Schatz DA, Shuster JJ, Atkinson MA.

Diabetologia. 2016 Jan;59(1):217-221. doi: 10.1007/s00125-015-3752-z. Epub 2015 Sep 10.

47.

Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes.

Mathews CE, Xue S, Posgai A, Lightfoot YL, Li X, Lin A, Wasserfall C, Haller MJ, Schatz D, Atkinson MA.

Diabetes. 2015 Nov;64(11):3885-90. doi: 10.2337/db15-0449. Epub 2015 Jul 27.

48.

Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.

Cani AK, Hovelson DH, McDaniel AS, Sadis S, Haller MJ, Yadati V, Amin AM, Bratley J, Bandla S, Williams PD, Rhodes K, Liu CJ, Quist MJ, Rhodes DR, Grasso CS, Kleer CG, Tomlins SA.

Mol Cancer Res. 2015 Apr;13(4):613-9. doi: 10.1158/1541-7786.MCR-14-0578. Epub 2015 Jan 15.

49.

Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes.

Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, Goland RS, Greenberg EM, Liljenquist DR, Ahmann AJ, Marcovina SM, Peters AL, Beck RW, Greenbaum CJ; T1D Exchange Clinic Network.

Diabetes Care. 2015 Mar;38(3):476-81. doi: 10.2337/dc14-1952. Epub 2014 Dec 17.

PMID:
25519448
50.

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.

Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA.

J Clin Invest. 2015 Jan;125(1):448-55. doi: 10.1172/JCI78492. Epub 2014 Dec 15.

Supplemental Content

Loading ...
Support Center